View the Sarepta Summer 2019 Newsletter HERE.
The latest edition of the Catabasis Connection newsletter discusses Phase 3 PolarisDMD trial for edasalonexent in Duchenne. Read the full newsletter here.
WAVE Open Letter to Community
In the latest Catabasis Connection, they take us behind-the-scenes with the PolarisDMD experience. Learn what it’s like to participate in their PolarisDMD clinical trial. Read the full newsletter here.
With a flurry of recent activity, 17 trial sites are now open for enrollment. We are especially excited to share that our first international sites in Canada and Australia have […]
SRPT press release – golodirsen NDA acceptance 02 14 19
We are excited that our industry partner, NS Pharma, has applied for accelertated approval for it’s exon 53 skipping therapy, viltolarsen. We applaud the dedication to the Duchenne community by […]
Dear Duchenne Advocacy Leaders, Lately we have heard many stop to consider the progress made in the last decade in Duchenne treatment and care. Improvements have been driven by this […]